Patient-Derived Gastric Cancer Assembloids: Modeling Tumor Microenvironment and Drug Response

Study Background and Research Question

Gastric cancer remains a major global health concern, ranking as one of the most frequently diagnosed carcinomas and a leading cause of cancer-related mortality. Tumor heterogeneity and the complex interplay between malignant epithelial cells and the surrounding stromal microenvironment pose significant challenges for effective therapy. Conventional three-dimensional (3D) organoid models, while valuable for recapitulating certain aspects of tumor architecture, often fail to represent the diverse stromal populations—such as cancer-associated fibroblasts and endothelial cells—that critically influence tumor progression, immune evasion, and drug resistance. The reference study by Shapira-Netanelov et al. (Cancers 2025, 17, 2287) addresses this gap by asking: Can an integrated assembloid model incorporating matched tumor organoids and autologous stromal subpopulations provide a more accurate and translationally relevant platform for gastric cancer research and personalized drug discovery?

Key Innovation from the Reference Study

The principal innovation of this work is the development of a patient-derived gastric cancer assembloid system that combines tumor organoids with multiple stromal cell types, all isolated from the same primary tumor specimen. This approach contrasts with previous models that typically culture tumor epithelium in isolation or use non-matched stromal cells, thus neglecting the unique, patient-specific microenvironmental context. By integrating mesenchymal stem cells, fibroblasts, and endothelial subpopulations alongside tumor cells, the assembloid model more closely mimics the cellular heterogeneity of the in vivo tumor microenvironment. This enables mechanistic exploration of how stromal components modulate gene expression, cell–cell interactions, and, critically, drug response—including the emergence of resistance to targeted therapies.

Methods and Experimental Design Insights

The methodology centers on dissociating freshly resected gastric tumor tissue into single cell suspensions, followed by expansion in lineage-specific media to selectively culture organoids (epithelial), mesenchymal stem cells, fibroblasts, and endothelial cells. These tumor-matched populations are recombined in a custom co-culture medium optimized to support the growth and survival of all included cell types. The resulting assembloids are evaluated for cellular composition and marker expression via immunofluorescence, while transcriptomic analysis (RNA sequencing) is used to assess gene expression profiles characteristic of tumor and stromal lineages. Drug sensitivity is measured using cell viability assays after treatment with various therapeutic agents, allowing direct comparison of drug response between pure organoid and complex assembloid models.

Protocol Parameters

• Tissue dissociation: Enzymatic and mechanical dissociation of gastric tumor tissue to obtain single-cell suspensions for downstream culture.
• Selective expansion: Use of lineage-appropriate media to expand organoid, mesenchymal, fibroblast, and endothelial fractions separately.
• Assembloid assembly: Co-cultivation of the matched subpopulations in an optimized medium that supports multi-lineage growth and cell–cell interaction.
• Biomarker analysis: Immunofluorescent staining for epithelial and stromal markers to confirm cellular composition.
• Transcriptomic profiling: RNA-seq to characterize differential gene expression influenced by stromal integration.
• Drug response: Cell viability assays following exposure to candidate agents, with comparisons drawn between organoid-only and assembloid models.

Core Findings and Why They Matter

The gastric cancer assembloids generated under these conditions exhibited cellular heterogeneity, stromal marker expression, and transcriptomic profiles closely resembling those of the original patient tumors (reference study). Notably, assembloids displayed elevated expression of inflammatory cytokines, extracellular matrix components, and tumor progression-associated genes compared to organoid monocultures. Assessment of drug responsiveness revealed substantial patient-to-patient and drug-specific variability. Crucially, some agents that showed efficacy in organoid models lost their potency in the assembloid context—highlighting the stromal microenvironment as a key modulator of therapeutic response and a potential driver of drug resistance. These results underscore the utility of assembloid systems for preclinical evaluation of targeted therapies and for uncovering mechanisms underlying resistance, which are often masked in simpler models.

Comparison with Existing Internal Articles

Several recent internal reviews have explored the relevance of advanced assembloid models and targeted therapies such as Gefitinib (ZD1839) in the context of complex tumor microenvironments:

• The article "Gefitinib (ZD1839) in Personalized Cancer Models" discusses how EGFR inhibitors like Gefitinib interact with patient-derived assembloid formats, offering mechanistic insights into EGFR signaling pathway inhibition and resistance mechanisms.
• "Gefitinib (ZD1839): Reimagining Selective EGFR Inhibition" further explores how assembloid models can help dissect the interplay between EGFR pathway activity, cell cycle arrest at G1 phase, and apoptosis induction in cancer cells—directly linking these mechanistic endpoints to the modulation of stromal influence and drug response.
• The review "Patient-Derived Gastric Cancer Assembloids Enhance Drug Testing" highlights the increased physiological relevance and predictive power of assembloids compared to traditional organoid systems, echoing the findings of the reference study.

Together, these articles reinforce the value of using assembloid models for translational drug testing and suggest that targeted agents, including selective EGFR inhibitors for cancer therapy, may require reassessment in microenvironment-mimicking platforms to understand resistance and optimize efficacy.

Limitations and Transferability

Despite its strengths, the assembloid platform has limitations. The protocols are technically demanding, requiring access to fresh patient tissue, specialized media, and expertise in multi-lineage culture. While the model enhances physiological relevance, certain elements of the immune microenvironment are not fully recapitulated, and the scalability for high-throughput screening remains constrained. Transferability to other cancer types is conceptually feasible, but adaptation of protocols and validation for specific tumor-stroma compositions are necessary. Furthermore, while the assembloid system provides a robust tool for preclinical research and resistance mechanism discovery, translation to clinical decision-making must be approached cautiously and in conjunction with additional in vivo and clinical validation.

Research Support Resources

For researchers aiming to study EGFR signaling pathway inhibition, apoptosis induction in cancer cells, and cell cycle arrest at G1 phase within physiologically relevant tumor models such as assembloids, the use of selective EGFR inhibitors remains essential. Gefitinib (ZD1839) (SKU A8219) from APExBIO is widely used in preclinical studies for its potent, well-characterized inhibition of EGFR tyrosine kinase activity, supporting both mechanistic investigation and drug response profiling. Researchers can follow the recommended protocols for in vitro application (typically 1 μM for 24 hours) or in vivo oral administration (200 mg/kg/day) as described in the product information to model key aspects of resistance and pathway modulation in advanced assembloid systems.